{
    "clinical_study": {
        "@rank": "14827", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "LX4211 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 2 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK),\n      safety and efficacy of LX4211 following daily oral administration for 29 days in patients\n      with type 1 diabetes mellitus (T1DM)."
        }, 
        "brief_title": "Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus", 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u226518 to \u226455 years of age\n\n          -  Confirmed diagnosis of T1DM, diagnosed prior to age 40 years, and for at least 6\n             months prior to Screening\n\n          -  Willing to refrain from using carbohydrate counting to adjust insulin during the\n             study\n\n          -  Willing and able to wear and operate a continuous glucose monitor\n\n          -  Willing and able to self-assess blood-glucose\n\n          -  Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  History of type 2 diabetes mellitus or diabetes resulting from acromegaly, Cushing's\n             disease, chronic pancreatitis, or pancreatectomy\n\n          -  Two or more severe episodes of hypoglycemia that required emergency treatment within\n             3 months prior to Screening\n\n          -  Use of premixed insulin\n\n          -  History of diabetic ketoacidosis within 1 year of screening\n\n          -  Presence of active hepatic disease or clinically significant abnormal liver function\n             tests\n\n          -  History of chronic pancreatitis\n\n          -  Subjects with a history of heart attack, severe/unstable angina, or coronary\n             revascularization procedure\n\n          -  History of clinically significant cardiac arrhythmias within 1 year prior to\n             screening\n\n          -  Subjects with congestive heart failure\n\n          -  Subjects with uncontrolled Stage III hypertension\n\n          -  History of human immunodeficiency virus (HIV) or hepatitis C\n\n          -  History of illicit drug or alcohol abuse within 12 months prior to Screening\n\n          -  Use of any investigational agent or device within 30 days prior to Screening or any\n             therapeutic protein or antibody within 90 days prior to Screening\n\n          -  Use of medication or herbal supplements taken for weight loss within 2 weeks of\n             screening\n\n          -  Chronic use of any antidiabetic therapy other than insulin within 2 months prior to\n             Screening\n\n          -  Use of systemic or inhaled corticosteroids within 2 weeks prior to Screening\n\n          -  Subjects who have undergone major surgery within 6 months prior to Screening\n\n          -  Inability or difficulty swallowing whole tablets or capsules\n\n          -  Women who are pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742208", 
            "org_study_id": "LX4211.1-203-T1DM", 
            "secondary_id": "LX4211.203"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "Subjects will receive LX4211 once daily for 29 days", 
                "intervention_name": "LX4211", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LX4211 Placebo", 
                "description": "Subjects will receive LX4211 placebo once daily for 29 days", 
                "intervention_name": "LX4211 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30318"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baton Rouge", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70808"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68131"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10467"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27713"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Lexicon Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Paul Strumph, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To assess the effect of LX4211 on the total daily bolus amount of exogenous insulin required to maintain or improve glycemic control", 
            "safety_issue": "No", 
            "time_frame": "Daily, Baseline through Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess total exogenous daily bolus and basal insulin use", 
                "safety_issue": "No", 
                "time_frame": "Daily, Baseline through Day 28"
            }, 
            {
                "measure": "Assess the amount of exogenous use at each meal", 
                "safety_issue": "No", 
                "time_frame": "Daily, Baseline through Day 28"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Days -1, 1-3, 8, 13, 28-31 and 37"
            }, 
            {
                "measure": "Change in glucose levels as measured by Continuous Glucose Monitoring (CGM)", 
                "safety_issue": "No", 
                "time_frame": "Week 1 through week 5"
            }, 
            {
                "measure": "Change in postprandial glucose by Area Under Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29; predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post-dose"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}